# Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

> **NCT00110149** · PHASE2 · TERMINATED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **RADIATION:** yttrium Y 90 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT00110149
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** 2012-05
- **Final completion:** 2015-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Company withdrew drug supply
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110149, "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00110149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*